Profile data is unavailable for this security.
About the company
WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.
- Revenue in HKD (TTM)18.40bn
- Net income in HKD2.83bn
- Incorporated2014
- Employees12.44k
- LocationWuXi Biologics (Cayman) IncNo. 108, Meiliang Road, MashanWUXI ChinaCHN
- Websitehttps://www.wuxibiologics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ascentage Pharma Group International | 970.97m | -387.39m | 13.33bn | 574.00 | -- | 16.15 | -- | 13.73 | -1.34 | -1.34 | 3.34 | 2.62 | 0.2998 | 3.49 | 2.19 | 1,665,471.00 | -11.97 | -44.93 | -16.78 | -57.04 | 96.96 | 87.68 | -39.93 | -976.10 | 1.83 | -8.16 | 0.6865 | -- | 5.85 | 100.76 | -4.84 | -- | 2.82 | -- |
| Genscript Biotech Corp | 7.86bn | -1.38bn | 22.87bn | 7.28k | -- | 2.41 | -- | 2.91 | -0.6509 | -0.6509 | 3.72 | 4.45 | 0.3006 | 9.15 | 7.99 | 1,132,728.00 | -9.68 | -18.34 | -14.76 | -26.15 | 53.63 | 54.68 | -32.19 | -64.91 | 4.06 | -- | 0.1972 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 2.02bn | -250.29m | 38.35bn | 1.54k | -- | 11.11 | -- | 19.00 | -1.11 | -1.11 | 9.12 | 15.48 | 0.5869 | 9.46 | 167.74 | 1,426,347.00 | -7.28 | -- | -16.56 | -- | 61.81 | -- | -12.40 | -- | 5.59 | -- | 0.0118 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
| Akeso Inc | 2.02bn | -790.66m | 63.14bn | 2.82k | -- | 10.84 | -- | 31.33 | -0.9412 | -0.9412 | 2.40 | 6.49 | 0.1925 | 0.3707 | 5.27 | 725,393.00 | -8.18 | -11.59 | -9.19 | -13.87 | 92.21 | -- | -42.50 | -42.49 | 4.43 | -5.49 | 0.3922 | -- | 440.35 | 337.43 | 273.60 | -- | 63.99 | -- |
| WuXi Biologics (Cayman) Inc | 18.40bn | 2.83bn | 63.82bn | 12.44k | 23.46 | 1.46 | 13.15 | 3.47 | 0.6547 | 0.6547 | 4.28 | 10.53 | 0.3163 | 5.35 | 2.98 | 1,444,600.00 | 5.57 | 8.28 | 6.85 | 10.25 | 38.66 | 43.25 | 17.60 | 27.46 | 2.62 | -- | 0.0928 | 0.00 | 11.56 | 46.38 | -23.09 | 40.07 | 20.32 | -- |
Data as of Nov 22 2024. Currency figures normalised to WuXi Biologics (Cayman) Inc's reporting currency: Hong Kong Dollar HKD
14.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 06 Nov 2024 | 127.45m | 3.07% |
| Schroder Investment Management Ltd.as of 30 Sep 2024 | 73.24m | 1.76% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 67.56m | 1.63% |
| BlackRock Fund Advisorsas of 08 Aug 2024 | 66.89m | 1.61% |
| Schroder Investment Management (Hong Kong) Ltd.as of 31 Jul 2024 | 56.94m | 1.37% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 55.92m | 1.35% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 49.95m | 1.20% |
| Hang Seng Investment Management Ltd.as of 08 Nov 2024 | 46.40m | 1.12% |
| BlackRock Advisors (UK) Ltd.as of 08 Aug 2024 | 42.28m | 1.02% |
| JPMorgan Investment Management, Inc.as of 16 May 2024 | 31.09m | 0.75% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
